In this article, we will take a look at the 12 Best Short Squeeze Stocks to Buy Right Now.
As the year comes to a close, investors are keeping close tabs on the Federal Reserve’s impending policy move, given the US shutdown-induced data shortage. Following the delayed September retail sales and wholesale inflation numbers, which fell short, markets are estimating a December quarter-point rate decrease with a likelihood exceeding 80%. Labor market indicators also reflect weakening, which may encourage officials to make cuts.
Meanwhile, politics at the central bank continue to heat up, with five candidates on President Trump’s shortlist to succeed Chair Jerome Powell next year.
In such a climate, several banks forecast strong market growth for the S&P 500 in the following year. In a revised outlook issued on November 25, Deutsche Bank set a price goal of 8,000 for the benchmark index at the end of 2026, citing “mid-teens returns” from greater inflows, buybacks, and ongoing earnings strength. Wells Fargo had similar comments, predicting a two-stage rally next year as the market transitions from a “reflation hope” trade in the first half to a greater AI-driven rise in the second half.
Image by Nattanan Kanchanaprat from Pixabay
Our Methodology
To compile our list of the best short squeeze stocks, we made use of stocks screeners to note down stocks with significant short interest. From that list, we primarily chose stocks with a short float of 20% or above. Additionally, we have mentioned the hedge fund sentiment around each stock, as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
12. CRISPR Therapeutics AG (NASDAQ:CRSP)
short % of float: 23.03%
Number of Hedge Fund Holders: 21
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its Market Outperform rating and $86 price target for CRISPR Therapeutics AG (NASDAQ:CRSP) on November 11. The firm discussed positive findings from CRISPR’s American Heart Association presentation on CTX310, targeted at ANGPTL3 for a variety of cholesterol issues.
Following the weekend data presentation, Citizens voiced optimism regarding CRISPR’s in-vivo projects. The firm noted some major catalysts, including in-vivo cardiovascular and alpha-1 antitrypsin deficiency updates in 2026, as well as a pediatric review for Casgevy at the American Society of Hematology meeting in 2025.
In addition, CRISPR’s third-quarter Casgevy sales fell short of forecasts, totaling $17 million compared to a consensus estimate of $41 million, with infusions falling from 16 in the second quarter to 10 in the current quarter. Nonetheless, CRISPR Therapeutics AG (NASDAQ:CRSP) remains confident about the Casgevy launch, citing increased cell collection numbers (45 vs. 25 in the second quarter) and a new reimbursement arrangement with Italy.
CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology that uses its proprietary gene sequencing platform to develop precise treatments for diseases that require DNA modification.
11. Lucid Group Inc. (NASDAQ:LCID)
short % of float: 34.36%
Number of Hedge Fund Holders: 21
Lucid Group Inc. (NASDAQ:LCID) ranks among the best short squeeze stocks to buy right now. On November 13, Benchmark reduced its price target for Lucid Group Inc. (NASDAQ:LCID) from $70 to $30, although it retained its Buy rating for the EV manufacturer’s shares. The decrease comes after Lucid Group Inc. (NASDAQ:LCID) announced in its Q3 report that it was pricing $875 million in senior unsecured convertible notes that are due in November 2031, along with a $100 million greenshoe option.
Lucid Group Inc. (NASDAQ:LCID) intends to use the proceeds for general corporate operations and to buy back a significant portion of its 1.25% 2026 notes, which have a principal of roughly $756 million for around $752 million in cash.
In addition, Lucid Group Inc. (NASDAQ:LCID) announced that its revenue for the third quarter of 2025 increased by a notable 68% year-over-year to $337 million. The company also shipped 4,078 vehicles, a 47% increase over the previous year. Despite revenue increases, Lucid’s adjusted EBITDA turned out to be $718 million loss.
Lucid Group Inc. (NASDAQ:LCID) is an electric vehicle manufacturer specializing in luxury electric cars. The company is famous for its high-performance vehicles with advanced battery technology.
10. SailPoint, Inc. (NASDAQ:SAIL)
short % of float: 23.73%
Number of Hedge Fund Holders: 25
SailPoint, Inc. (NASDAQ:SAIL) ranks among the best short squeeze stocks to buy right now. On November 18, TD Cowen reiterated its Buy rating and $30 price target for SailPoint Technologies Holdings (NASDAQ:SAIL), ahead of the company’s third-quarter earnings report on December 9. The firm anticipates SailPoint to exceed its conservative projection of $49 million in net new annual recurring revenue (NNARR), representing a 6% year-over-year increase.
In its Q2 earnings report, SailPoint, Inc. (NASDAQ:SAIL) revealed that it expects Q3 revenue between $269 million and $271 million, with recurring revenue growing 26% to 27% year-over-year. SailPoint, Inc. (NASDAQ:SAIL) also boosted its FY2026 guidance on all major metrics. It now anticipates revenue between the $1.052 billion and $1.058 billion range, ARR between $1.105 billion and $1.115 billion, and adjusted earnings per share (non-GAAP) around $0.20 and $0.22.
According to TD Cowen’s analysis, there is still substantial demand for vendors who provide comprehensive identity governance solutions, which are essential to SailPoint’s business model.
SailPoint, Inc. (NASDAQ:SAIL) provides enterprise identity security solutions by unifying identity data across employees, contractors, machines, and AI agents. The company’s products includes identity security cloud, atlas, connectivity and integrations, and identityIQ software platforms.
9. Plug Power Inc. (NASDAQ:PLUG)
short % of float: 23.54%
Number of Hedge Fund Holders: 27
Plug Power Inc. (NASDAQ:PLUG) ranks among the best short squeeze stocks to buy right now. On November 19, TD Cowen maintained its Buy rating for Plug Power Inc. (NASDAQ:PLUG) but lowered its price target to $4 from $4.50. The change comes after Plug Power’s most recent symposium, which featured client endorsements of the company’s value proposition.
TD Cowen claims that Plug Power Inc. (NASDAQ:PLUG) remains focused on execution in order to grow its material-handling and electrolyzer businesses while moving closer to profitability.
The firm also pointed out that the stock price has suffered as a result of Plug Power’s announcement of a convertible offering following market close, which was primarily meant to refinance 15% of the company’s debt.
Plug Power Inc. (NASDAQ:PLUG) announced the pricing of a $375 million convertible senior notes issuance scheduled for 2033 at a 6.75% rate. The company estimates net proceeds of about $347.2 million from this transaction.
Plug Power Inc. (NASDAQ:PLUG) provides alternative energy technology focusing on the development, design, manufacturing, and commercialization of hydrogen and fuel cell systems that are primarily employed for the material handling and stationary power markets.
8. Centrus Energy Corp. (NYSE:LEU)
short % of float: 26.51%
Number of Hedge Fund Holders: 31
Centrus Energy Corp. (NYSE:LEU) ranks among the best short squeeze stocks to buy right now. Following a post-earnings non-deal roadshow with management on November 7, Daiwa Securities reaffirmed its Buy rating and $86 price target for Centrus Energy Corp. (NYSE:LEU) on November 10. The firm cited Centrus’s prediction that the U.S. market will experience a severe lack of uranium enrichment supply beginning in 2028.
According to Daiwa, the expected supply interruption is driven by the Russian import waiver expiring at the end of 2027, which would cut off about 25% of the supply of uranium enrichment in the U.S. market.
Additionally, Centrus Energy Corp. (NYSE:LEU) faced pressure after announcing that it had entered into an ATM equity offering sales agreement that will enable it to put up around $1 billion in Class A common stock, with the proceeds going toward general financing and company goals.
Evercore ISI, maintaining an Outperform rating on LEU stock, described the company’s ATM announcement as a smart measure to raise capital when available as opposed to a reactionary move, noting that SWU prices continue to rise even after being “artificially depressed” at the present price of approximately $220/SWU.
Centrus Energy Corp. (NYSE:LEU) is a Maryland-based supplier of nuclear fuel components and services that operates under two business categories: Low-Enriched Uranium and Technical Solutions.
7. Viking Therapeutics, Inc. (NASDAQ:VKTX)
short % of float: 22.01%
Number of Hedge Fund Holders: 37
Viking Therapeutics, Inc. (NASDAQ:VKTX) ranks among the best short squeeze stocks to buy right now. On November 20, H.C. Wainwright retained its Buy rating and $102 price target for Viking Therapeutics, Inc. (NASDAQ:VKTX) following the end of enrollment in the company’s VANQUISH-1 obesity trial.
The trial, which enrolled around 4,650 individuals, concluded ahead of schedule and will compare three different doses to a placebo over a 78-week period. VANQUISH-2, the company’s second trial, which aims to enroll around 1,100 people with type 2 diabetes who happen to be obese or overweight, is still enrolling and is expected to be completed in the first quarter of 2026.
Viking Therapeutics, Inc. (NASDAQ:VKTX) also released exploratory analysis data from its Phase 2 VENTURE trial at ObesityWeek 2025 on November 6, demonstrating significant improvements in cardiometabolic measures among obese patients. Notably, 78% of prediabetic individuals who received VK2735 had normal glycemic control after 13 weeks, as opposed to 29% in the placebo group.
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company developing treatments for metabolic and endocrine disorders, including obesity, NASH, and rare diseases like X-linked adrenoleukodystrophy (X-ALD).
6. Sunrun Inc. (NASDAQ:RUN)
short % of float: 24.48%
Number of Hedge Fund Holders: 39
Sunrun Inc. (NASDAQ:RUN) ranks among the best short squeeze stocks to buy right now. On November 12, Mizuho reaffirmed its Outperform rating and $25 price target for Sunrun Inc. (NASDAQ:RUN), emphasizing the company’s recently proven capacity to realize upfront sales and offer new customer originations to third parties.
This comes after Sunrun’s Q3 earnings call, in which the company revealed revenues of $724.56 million, exceeding forecasts by 20.64%, and EPS of $0.06, falling short of the $0.13 estimate by 53.85%. According to Mizuho’s estimate, Sunrun Inc. (NASDAQ:RUN) also made about $108 million in cash during the quarter despite having a lower net margin.
Mizuho noted that Sunrun’s safe harbor data supports potential customer growth of as much as twofold over the next four years, which is consistent with the company’s growth projections.
Sunrun Inc. (NASDAQ:RUN) is a leading provider of residential solar and battery storage, offering clean energy solutions to homeowners with a focus on subscription services that require little to no upfront cost. In addition to managing energy services that can help households and the electrical grid, the company designs, installs, and maintains solar panels and storage systems.
5. Immunovant, Inc. (NASDAQ:IMVT)
short % of float: 22.01%
Number of Hedge Fund Holders: 40
Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to buy right now. Following the company’s fiscal second-quarter 2026 financial results, Oppenheimer reaffirmed its Outperform rating on Immunovant, Inc. (NASDAQ:IMVT) on November 11 with a price target of $54. The company’s reported earnings per share of -$0.73 fell short of the -$0.71 consensus estimate. With $4.4 billion in cash and no debt on its balance sheet, Immunovant, Inc. (NASDAQ:IMVT) maintains a strong capital position in despite these deficits.
The company intends to publish results from a proof-of-concept study in cutaneous lupus and preliminary clinical data for IMVT-1402 in ACPA+ difficult-to-treat rheumatoid arthritis in 2026. According to Oppenheimer, the medication is “positioned as best-in-class” and has “considerable upside” as it moves closer to possible commercialization across multiple indications.
Immunovant, Inc. (NASDAQ:IMVT) is also testing a second drug candidate, batoclimab, in mid-late-stage trials for two separate autoimmune conditions: GD and thyroid eye disease (TED).
Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage immunology company focused on developing innovative therapies for autoimmune diseases. The company’s primary focus is on creating anti-FcRn (neonatal Fc receptor) antibodies which aim to reduce harmful immunoglobulin G (IgG) autoantibodies in patients with various autoimmune conditions.
4. Under Armour Inc. (NYSE:UA)
short % of float: 27.46%
Number of Hedge Fund Holders: 41
Under Armour Inc. (NYSE:UA) ranks among the best short squeeze stocks to buy right now. Telsey Advisory Group announced on November 18 that Under Armour Inc. (NYSE:UA) and basketball player Stephen Curry will part ways in 2026 after a 12-month wind-down period. The firm reiterated its Market Perform rating and $5 price target for the company’s shares.
The basketball division of Under Armour, which includes the Curry brand, is expected to generate around $100 million – $120 million in revenue during the current fiscal year. This amounts to roughly 10% of Under Armour’s footwear sales and 2% of the company’s overall revenues. The company further stated that Under Armour’s financial performance and profitability are unlikely to be “significantly affected” by the split.
The Curry 13, Stephen Curry’s last signature shoe, will be released in February of next year, with more colors and apparel collaborations possible until October 2026, marking the conclusion of the collaboration that started in 2013.
Under Armour Inc. (NYSE:UA) is a global leader in performance apparel, footwear, and accessories. It caters to athletes and active individuals of all ages. Its product portfolio spans compression wear to specialized footwear. Its distribution network encompasses wholesale, retail, and e-commerce.
3. TeraWulf Inc. (NASDAQ:WULF)
short % of float: 41.98%
Number of Hedge Fund Holders: 47
TeraWulf Inc. (NASDAQ:WULF) ranks among the best short squeeze stocks to buy right now. Following TeraWulf Inc. (NASDAQ:WULF)’s third-quarter 2025 earnings report, Citizens reaffirmed its Market Outperform rating and $22 price target on November 11.
TeraWulf’s performance in the third quarter of 2025 came in relatively mixed. The company revealed a larger-than-expected loss with earnings per share of -$1.13 relative to the expected -$0.05, though it reported a 6% quarter-over-quarter growth in GAAP revenues to $50.6 million. However, the company’s total profitability was impacted by the 22% drop in self-mined Bitcoins from the previous quarter. On the other hand, TeraWulf Inc. (NASDAQ:WULF) stated that it intends to boost its high-performance computing (HPC) capacity by 250–500 megawatts annually.
Citizens stated that TeraWulf Inc. (NASDAQ:WULF) has evolved from a “highly-speculative operation” to a company with “a line of sight to rapidly exhausting the capacity of its two initial sites,” citing new anchor tenant clients who have shown the company’s reliability.
TeraWulf Inc. (NASDAQ:WULF) develops, owns, and operates industrial-scale data center infrastructure in the US that is designed specifically for Bitcoin mining and high-performance computing (HPC) hosting.
2. IREN Limited (NASDAQ:IREN)
short % of float: 21.72%
Number of Hedge Fund Holders: 52
IREN Limited (NASDAQ:IREN) ranks among the best short squeeze stocks to buy right now. On November 19, Citizens began coverage of IREN Limited (NASDAQ:IREN) with a $80 price target and a Market Outperform rating. The firm emphasized IREN’s strategic shift from bitcoin mining to providing services in the AI industry’s high-performance computing (HPC) segment, emphasizing the company’s “different approach with significant power supply.”
This comes after IREN Limited (NASDAQ:IREN) and Microsoft signed a notable $9.7 billion deal. According to the agreement, Microsoft will employ IREN’s data-center capacity, largely located at its 750-megawatt Childress, Texas facility, to expand its AI cloud services. As part of the contract, Microsoft will make a 20% prepayment, and IREN Limited (NASDAQ:IREN) will purchase around $5.8 billion in GPUs and hardware from Dell to meet rollout requirements.
Citizens noted that, while the GPUaaS model offers quicker returns and greater yield than traditional leasing, it “will also likely become much more competitive over time.”
IREN Limited (NASDAQ:IREN), a Bitcoin mining and AI data center company across North America, provides high-performance computing infrastructure and GPU-based cloud services to enterprises and institutional clients.
1. Core Scientific, Inc. (NASDAQ:CORZ)
short % of float: 20.67%
Number of Hedge Fund Holders: 68
Core Scientific, Inc. (NASDAQ:CORZ) ranks among the best short squeeze stocks to buy right now. On November 5, Ladenburg Thalmann raised its price target for Core Scientific, Inc. (NASDAQ:CORZ) from $22.50 to $24.50, while maintaining its Buy rating for the company. The firm justified the higher target by pointing to potential earnings from High-Performance Computing and projected growth in Core Scientific’s hashrate.
According to Ladenburg Thalmann, Core Scientific’s non-GAAP cash earnings will amount to $461 million, or $0.92 per share, while its calendar 2027 revenues will grow to $1.055 million.
The firm pointed out that Core Scientific’s break-even mining price remains far below current and anticipated Bitcoin prices, enabling sustained profitable operations despite volatility.
This follows Core Scientific, Inc.’s announcement that the proposed merger with CoreWeave, Inc. was terminated due to the shareholders’ disapproval. As a result, the July 2025 merger agreement has been officially dissolved.
Core Scientific, Inc. (NASDAQ:CORZ) operates digital Bitcoin mining and high-performance computing infrastructure. The company leverages its own fleet of computers, called miners, to earn Bitcoin for its own account and also provides hosting services for Bitcoin mining and high-performance computing customers at eight US-based operational data centers.
While we acknowledge the potential of CORZ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CORZ and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
